Kintor Pharmaceutical Ltd banner

Kintor Pharmaceutical Ltd
HKEX:9939

Watchlist Manager
Kintor Pharmaceutical Ltd Logo
Kintor Pharmaceutical Ltd
HKEX:9939
Watchlist
Price: 3.99 HKD -0.99% Market Closed
Market Cap: HK$2B

Wall Street
Price Targets

Price Targets Summary
Kintor Pharmaceutical Ltd

There are no price targets for Kintor Pharmaceutical Ltd.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
Kintor Pharmaceutical Ltd Competitors:
Price Targets
SPWH
Sportsmans Warehouse Holdings Inc
134% Upside
PRQR
ProQR Therapeutics NV
422% Upside
TELA
TELA Bio Inc
378% Upside
BRI
Britania PCL
10% Upside
PRDO
Perdoceo Education Corp
24% Upside

Revenue
Forecast

N/A
Past Growth
32 960% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
N/A
Past Growth
32 960% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

The compound annual growth rate of Kintor Pharmaceutical Ltd's revenue for the next 1 year is 32 960%.

Operating Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
1%
Average Beat
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
1%
Average Beat

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-15%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-15%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is Kintor Pharmaceutical Ltd's stock price target?
Not Available

Kintor Pharmaceutical Ltd doesn't have any price targets made by Wall Street professionals.

What is Kintor Pharmaceutical Ltd's Revenue forecast?
Projected CAGR
32 960%

The compound annual growth rate of Kintor Pharmaceutical Ltd's revenue for the next 1 year is 32 960%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett